The name, location, and philosophy of Neusentis epitomises the future of drug discovery and development at Pfizer.
It represents a team of scientists with endless curiosity and scientific courage working in partnership with academic researchers in Cambridge and around the globe to change the lives of patients suffering from pain, and other diseases and disorders for which there are no therapies or cures.
Our Vision is to deliver medicines that provide real and significant benefit to the many individuals for whom existing therapeutic agents remain inadequate.
Icagen gets a new name after being acquired by Pfizer - 22 March 2012
Department of Molecular Biology, La Jolla, California 92037, USA.
Molecular Nociception Group, London, UK